Human blood plasma provides a highly accessible window to the proteome of any individual in health and disease. Since its inception in 2002, the Human Proteome Organization's Human Plasma Proteome Project (HPPP) has been promoting advances in the study and understanding of the full protein complement of human plasma and on determining the abundance and modifications of its components. In 2017, we review the history of the HPPP and the advances of human plasma proteomics in general, including several recent achievements. We then present the latest 2017-04 build of Human Plasma PeptideAtlas, which yields ~43 million peptide-spectrum matches and 122,730 distinct peptide sequences from 178 individual experiments at a 1% proteinlevel FDR globally across all experiments. Applying the latest Human Proteome Project Data Interpretation Guidelines, we catalog 3509 proteins that have at least two non-nested uniquelymapping peptides of 9 amino acids or more and >1300 additional proteins with ambiguous evidence. We apply the same two-peptide guideline to historical PeptideAtlas builds going back to 2006 and examine the progress made in the past ten years in plasma proteome coverage. We also compare the distribution of proteins in historical PeptideAtlas builds in various RNA-abundance and cellular localization categories. We then discuss advances in plasma proteomics based on targeted mass spectrometry as well as affinity assays, which during early 2017 target ~2000
Introduction
Human blood is the most informative easily obtainable sample for assessing the wellness of an individual. Cells can be isolated to provide genomic, transcriptomic, proteomic, metabolomic, and epigenomic information, and the plasma can yield a wealth of systemic information based on the abundance of proteins, cell-free DNA and RNA, metabolites, lipids, and other small molecules. Blood is in contact with all internal organs and, therefore, contains signatures of normal function as well as the consequences of cellular damage and disease manifestation throughout the body. However, the abundances of proteins and other molecules vary across an enormous dynamic range (~10 13 range), making the task of detecting and quantifying low abundance signatures a difficult challenge (1) . The plasma proteome, therefore, is immensely important clinically and presents enormous analytical challenges.
As one of the very first initiatives of the Human Proteome Organization (2) (HUPO), the Human Plasma Proteome Project (HPPP) began in 2002 with the aim of establishing a comprehensive profile of the proteins present in human plasma in health and disease. The initial phase of the HPPP was a collaborative effort among 35 laboratories to catalog the human plasma proteome via mass spectrometry (MS) based on a set of defined reference samples of plasma and serum (3) . The HPPP continues its efforts to the present day with MS as well as exploring orthogonal technologies.
The global Human Proteome Project (HPP) was announced in 2010 at the 10 th HUPO World Congress in Sydney, Australia, with the aim of advancing our understanding of all proteins in the human proteome and making advanced protein measurement assays more accessible to the broader research community (4) . The HPP comprises a chromosome-centric project (C-HPP; launched at HUPO 2011 in Geneva, Switzerland) (5) that aims to identify and characterize all proteins, annotated in an internationally distributed fashion; a biology/ disease-focused project (B/D-HPP; launched at HUPO 2012 in Boston, USA) (6) that aims to understand better the complement of human proteins that are pertinent to a wide variety of human organ systems and biofluids in health and disease; and three resource pillars, including antibody profiling, mass spectrometry, and knowledge base/bioinformatics. The HPPP is one of the major initiatives of the B/D-HPP, focused on understanding the full complement of proteins that can be detected and measured in human plasma samples both in normal and diseased states.
In this article, we first provide a brief review of the advances of the HPPP and MS-based human plasma proteomics in general over the past 15 years. We present the latest and most comprehensive compendium of proteins that have been confidently detected in human plasma samples from the aggregated spectra generated in a large number of publicly available studies. We then discuss advances in MS, present other technologies beyond MS, and conclude with recommendations and an outlook for progress for the next five years.
Historical Perspective of Plasma Analysis with MS
The earliest large compendium of plasma proteins was presented in 2002 in the seminal article by Anderson & Anderson (1) . The list of 289 proteins was collected from literature of the day. In a classic figure, a subset of proteins with abundances was depicted over 10 orders of magnitude in abundance in normal plasma and grouped broadly into the categories of classical plasma proteins, tissue leakage products, and cytokines and other very low abundance proteins. Most of the proteins were listed in a table with typical reported concentrations from ELISA (or similar technology) measurements.
In 2003 the HPPP obtained and distributed a series of serum and EDTA-, citrate-, and heparin-anticoagulated plasma samples from Caucasian, African-American, and AsianAmerican individuals to 35 different laboratories to run across a range of MS instruments and analysis of choice and report the resulting lists of peptides and proteins. There was tremendous variability in the reported results, with some groups providing a rather shallow analysis of one or two of the distributed samples, while other groups provided a far deeper analysis with substantial fractionation of many more samples. This heterogeneity made it particularly difficult to compare results among different groups. In the final HPPP report (3), the number of non-redundant proteins with one or more peptides reported by any group was over 9000. A more conservative list of proteins with at least two reported peptides amounted to 3020 proteins and those with three peptides to 1500 proteins. The danger of very high numbers of false positives from combining many such data lists was explicitly suspected. A subsequent, far more conservative analysis of the results by the same HPPP investigators concluded that there existed high confidence evidence for 889 proteins (7) . This analysis uniquely used a Bonferroni-type adjustment for multiple comparisons. An independent analysis of the raw data from most (but not all) of the labs as well as some additional data sets yielded a similar estimate of 960 proteins (8) .
substantially inflated numbers due to improperly controlled false positives. In 2008, a meticulous manually-validated effort using the latest instrumentation yielded only 697 proteins, albeit with 144 immunoglobulin entries removed (9) . Although combining data sets from different investigators and platforms provides access to a higher number of legitimate detections, it also makes controlling the false discovery rate (FDR) far more challenging.
It was widely recognized that the most abundant proteins greatly complicated detection of much lower abundance proteins and their peptides. Antibody-based depletion of 1 (albumin), 6, 14, or 22 most abundant proteins (accounting for 50 to 99% of the protein mass) became common (10) (11) (12) , with deeper in-house depletion methods also recently developed (13, 14) .
Subsequently the PeptideAtlas resource collected many additional data sets from many different labs and provided substantial effort into controlling the FDR of the search results to provide a database of human plasma proteins with an approximate 1% FDR at the protein level across all experiments as an ensemble. In 2011 Farrah et al. reported 1929 proteins with a 1% protein-level FDR, along with estimated concentrations of the identified proteins based on PSM counting statistics across all datasets in the PeptideAtlas build (15) . In 2013, 3553 non-redundant proteins were reported (16) . In 2014, Farrah et al. extensively compared the proteomes of plasma, kidney, and urine, detecting proteins filtered from the plasma through the kidney to the urine, proteins appearing de novo in the urine, and proteins arising in the kidney (17) .
More recent work has pushed the number of confidently-identified plasma proteome even higher. Keshishian et al. (18) reported on human plasma derived from four patients undergoing a planned myocardial infarction procedure for hypertrophic cardiomyopathy. Plasma was sampled at multiple time points, depleted of the ~64 most abundant proteins, cleaved with two proteases, labeled with iTRAQ reagents, fractionated by pH 10 RP-HPLC into 30 concatenated pools, and analyzed with modern high resolution Q Exactive Plus Orbitrap instrumentation. Whereas 3400 proteins were quantified in every sample, a total of 5300 distinct protein entries were claimed in at least one of the samples, with an estimated protein-level FDR <0.02% (1 decoy/5304). Alternative strategies attempt to minimize the total analysis time in an effort to make plasma proteomic analyses more clinically accessible. Recent efforts achieve high quantitative repeatability of ~1000 proteins using a single MS run per sample (19) , in one case analyzing 1294 separate plasma proteomes (20) .
The Human Plasma PeptideAtlas 2017
The PeptideAtlas project (21-23) has been collecting shotgun proteomics datasets from labs all around the world since 2004, processing the raw data through a uniform analysis pipeline based on the Trans-Proteomic Pipeline (24) (25) (26) , and publicly releasing ensemble builds of all the processing results, for human and many other species for which substantial data were collected (27) (28) (29) (30) (31) (32) (33) (34) . For some species such as human, where samples from different tissue and biofluid type are available, PeptideAtlas has created special builds focusing only on a single sample type. The earliest such special build was for human plasma in 2005 (8) ; and this has been updated many times since. The Human Plasma PeptideAtlas has provided a publicly available, high stringency snapshot of the full complement of proteins detected in plasma in publicly available shotgun MS experiments over time since 2005.
Since our last publication in 2014 (17) , three additional builds have been released on-line in 2014 (unpublished), 2015 (unpublished), and 2017-04 (presented in this article). The latest build follows the same data analysis and FDR calculation procedures described in the 2014 publication, with the exception that the search database now used is the THISP database, which is based on neXtProt (Deutsch et al, JPR2016) . Thresholds for all individual datasets are set so that when all combined, the combined protein-level FDR is 1%, with a corresponding combined PSM-level FDR of 0.0005 and a combined peptide-level FDR of 0.004. Further statistical details are displayed on the build summary page at the PeptideAtlas interface. Figure 1 depicts the total number of distinct peptides as a function of the total number of PSMs passing threshold added to the Human Plasma PeptideAtlas over time from the earliest datasets to the most recent. The dramatic increase in the number of distinct peptides heralds the advent of the collection and analysis of high resolution MS2 spectra with Orbitrap-based instruments.
Supplementary Table 1 lists all 178 experiments included in the latest build. Each experiment represents a distinct analyzed sample. Some samples are single MS runs, while in most experiments samples were fractionated to reduce complexity before each fraction was analyzed in a separate LC-MS run. In many cases, data sets that are submitted as a single ProteomeXchange dataset are separated into individual experiments when they represent different samples. For each experiment, attributes such as the total number of MS2 spectra, number of PSMs passing threshold, number of distinct peptides, etc. are listed. The 2017-04 build now contains 122,730 distinct peptides (including many semi-tryptic ones) derived from over 43 million PSMs that pass threshold, selected from a total of 172 million spectra searched. The number of proteins listed in Supplementary Table 1 is somewhat higher than the 3509 number listed in other parts of this article because the numbers in the supplementary table includes contaminants, alternative splice isoforms, variable region immunoglobulin sequences, and other TrEMBL entries with apparently unique peptides mapping to them, while the 3509 number is limited to just the ~20,000 neXtProt protein entries.
In order to gain a historical perspective on the total number of proteins gained for each of our consecutive builds in a consistent manner, we have remapped all the peptides from these builds to the 2017-01 version of neXtProt using the AtlasProphet algorithm (23) . We have applied guideline # 15 of the HPP MS Dataset Interpretation Guidelines (35) such that for a protein to be listed as canonical in PeptideAtlas, it must have two distinct non-nested, uniquely mapping peptides of length ≥9 residues. In Figure 2 , we show the progression of the number of these canonical proteins over historical builds, culminating in 3509 proteins in the 2017-04 build. Note that these numbers are smaller from those quoted in previous publications because new, stricter requirements have been imposed on the older data to reduce misidentifications. In addition, there are 1337 proteins in the ambiguous category; these include proteins with only one peptide, peptides of insufficient length, and cases where the detected peptides cannot distinguish between members of a group, although clearly at least one of the members of the group has been detected. A further 1700 entries are in a redundant category, meaning that although there are peptides that map to these entries, those peptides are better assigned to a canonical or ambiguous protein using rules of parsimony.
In Figure 3 We have also estimated average protein concentrations for canonical proteins in the latest 2017 build as well as older builds in order to compare the distributions of concentrations of added proteins as the Atlas expands. Concentrations were estimated based on the total number of PSMs for canonical proteins, corrected for the number of expected tryptic peptides of suitable attributes, and calibrated against a list of known protein concentrations, a method previously described in detail for the 2010 Human Plasma PeptideAtlas build by Farrah et al. (36) . Figure 4 depicts the distribution of estimated protein concentrations from builds in 2010, 2013, 2015, and 2017. The mean of the distributions clearly moves to lower concentration from 2010 to 2013 to 2015. However, the shape of the distribution remains highly similar from 2015 to 2017, with very few proteins extending below 0.01 ng/ml estimated concentration. These concentrations are estimated based on a combination of all samples, which vary widely in instrumentation, quantification methods, degrees of fractionation, and sample preparation techniques. It would be useful to be able to estimate and provide plasma protein concentrations in specific physiological contexts or disease states, but data to provide that are not currently available; a highly uniform survey for plasma concentrations under carefully controlled specific physiological contexts or disease states would provide very valuable data.
All data associated with this build are made publicly available in the PeptideAtlas Data Repository and via links at http://www.peptideatlas.org/hupo/hppp/. This includes raw data and search results from each of the included experiments, listed with links at http:// www.peptideatlas.org/hupo/hppp/repository/. The data are available packaged in BDBags that are uniquely identified with Minids (37) . BDBags are compressed archives that contain embedded manifests and checksums that enable automated validation of completeness against the checksums. Minids provide a convenient and short minimal identifiers that can uniquely identify datasets and enable users to download and verify them using the associated toolset (http://minid.bd2k.org/).
Comparisons with RNA abundances
In order to compare the expansion of the proteome with overall RNA abundance, we group RNA abundance in tissues as compiled by the Human Protein Atlas (HPA; version 15) into four broad categories (high: FPKM > 50, medium: FPKM 10-50, low: FPKM 10-0.5; not detected: FPKM 0.5-0) (38, 39) ). We note that correlation between RNA abundances and protein abundances is a subject of extensive discussions and generally low (e.g. (40)), but the completeness of RNA abundances is far higher and enables nearly complete comparisons with several protein sets. In Table 1 we show the relative distributions of proteins within these high, medium, low and not detected categories. While 42% of the population of all protein-coding genes from Ensembl (release 88.38) falls into the high RNA-abundance category in highest-expressed tissues, a somewhat higher percentage (50%) of proteins detected in all human samples are in this high abundance category, and in the Plasma PeptideAtlas an even higher percentage (77%) are in this high RNA abundance category. The total number of plasma proteins differs slightly from the figure of 3509 in the abstract and other totals in this article because there is a small number of proteins that could not be mapped to the RNA expression tables.
The union of a broad range of immunoassays publicly available for plasma analysis during spring of 2017 was collected from five providers. The corresponding protein-coding genes for these targets were annotated with regards to their predicted location and RNA abundance In Table 2 , we show the distribution of proteins detected in the Human Plasma PeptideAtlas over time as a function of RNA abundance categories from the Human Protein Atlas. In 2009, only ~10% of the proteins in the Plasma PeptideAtlas were found in the medium and low RNA-abundance categories, while as of 2017, nearly a quarter of all high-confidence detections are proteins with corresponding medium and low RNA-abundance. The distributions of plasma protein concentrations in relation to these RNA expression categories can be found in Supplementary Figure 1 .
In Table 3 , we used the protein abundance from the 2017 Human Plasma PeptideAtlas to show the concentration distribution and increase in coverage from previous builds. A 33-fold increase in coverage was seen for low abundant proteins (< 0.1 ng/ml).
In Table 4 , we show the numbers and percentages of proteins in the Plasma PeptideAtlas builds since 2009 in relation to their localizations predicted from protein sequences (39, 41) . Between 2015 and 2017, the coverage for secreted proteins hardly changed, accompanied by a marked increase in the percentage of membrane and intracellular proteins. 
Targeted MS assays for the plasma proteome
While most of the efforts to expand the known plasma proteome have used shotgun proteomics techniques, the selected reaction monitoring (SRM) technique has been widely used to achieve more consistent, quantitative, and sensitive measurements of specific proteins of interest in plasma. SRM workflows are more difficult to deploy due to the requirement for predetermining effective signatures for each targeted protein, the need for spiking in heavy-labeled reference peptides for accurate quantitation, and the limited number (~200 -1000) of those signatures that can be monitored per MS run. However, this extra effort required to carry out measurements is offset by improved sensitivity and specificity, high degree of quantitative accuracy and reproducibility, and the determination of upper limits of abundance for each targeted peptide. The earliest work by Anderson & Hunter (42) developed targeted assays (also known as multiple reaction monitoring (MRM) targeting 53 high and medium abundance proteins over 4.5 logs in abundance with a coefficient of variation (CV) of < 10% for most of them. This was followed by many other studies that have defined and demonstrated the effectiveness of signatures for certain proteins of interest (43) (44) (45) (46) . Of particular interest was the deployment of SRM assays over several MS runs for over 1000 cancer associated proteins and the detection of 182 of these cancer associated proteins in plasma covering 5 orders of magnitude (47) .
To provide assistance in deploying targeted SRM assays, the SRMAtlas resource (48) was developed using highly characterized synthetic peptides representing the most proteotypic candidates of each protein, their variants, including spliced and non-synonymous variants, and some post-translational modifications. The human SRMAtlas has now determined recommended signatures for multiple peptides per protein for over 99% of all human proteins, enabling researchers to target any protein of interest without needing to undergo a lengthy signature selection process, fragment ion selection and SRM assay construction.
To further advance targeted quantitative proteomics, multiplexed fragment ion monitoring based assays have been developed into a technique, broadly termed data-independent acquisition (DIA), including SWATH-MS (49) . SWATH-MS promises to provide similar sensitivity and specificity as SRM, without the problems associated with selecting targets in advance, by utilizing a well characterized spectral library developed a priori or on the fly (50, 51) . In essence, high-resolution fragment ion data are collected for all peptides across chromatographic peaks above the detection threshold in a sample, but at the cost of substantially more complex informatics analysis after acquisition, which is needed to disentangle the high level of multiplexing in the data. DIA techniques perform well in comparison with SRM (52). Large scale-studies of over 1000 plasma proteins in many plasma samples are now feasible (53, 54) , and also enable the study of unexpected posttranslational modifications within the comprehensive multiplexed datasets (55, 56) .
Affinity assays for the plasma proteome
As described above, the main driving force for defining new components of the plasma proteome has been mass spectrometric. An alternative for determining the constituent proteins in plasma is the use of affinity reagents to capture, enrich, and detect their target proteins. The use of such assays has provided general as well as clinically applied insights into the protein composition of body fluids, starting from albumin down to low abundance molecules, such as cytokines.
Affinity-based approaches require knowledge about which proteins are to be measured, and hence are by definition targeted assays. A primary bottleneck for expansion to a wider range of proteins has been linked to the availability of affinity reagents (57) . According to Antibodypedia (www.antibodypedia.org; access date 2017-05-11; (58)) there are more than 2.8 million antibody reagents commercially available. Even though these cover 94% of the protein encoding genes, enormous effort is still required to validate and annotate their utility for the intended assay type and technology platform, as well as the sample type, preparation and formulation. For highly multiplexed assays, compatibility between different assay components also needs further attention. Recent discussions have indeed raised concerns about the reliability of affinity-based assays due to lack of reproducibility and specificity (59, 60) . The community has therefore brought forward suggestions for how to apply communal standards on how to validate these reagents (61) . The performance of reagents is indeed dependent on the application and sample type and needs to be assessed for every binder and every assay. A systematic approach using MS to qualify antibodies for their use in plasma proteomics assays has just recently been described (62) . While the generation of natural or synthetic affinity reagents is discussed in detail elsewhere (63) , and an increasing diversity of reagent types is making them attractive across the different fields of life science, they must be assessed separately for their use in plasma assays and the applied technologies.
Assay platforms
Today there are a variety of multiplexed assay technologies available to detect proteins in plasma (64) . Whereas affinity reagents are also used in combination with MS (65, 66) , the primary applications for plasma are driven towards high throughput assays in terms of sample and proteins. Here, multiplexing is achieved by different concepts such as coding the features either via their location (e.g. on a planar support or in channels) or with color or DNA barcode. Detection is then most often achieved via fluorescently labelled reporters or barcodes of oligonucleotides for amplification, hybridization or sequencing. A general feature of multiplexed affinity assays is that small quantities of samples (< 50 μl) suffice for a single highly multiplexed analysis or sets of medium-sized multiplexed analyses. Prefractionation is generally not required. In addition, larger sets of samples (N > 100) can be analyzed within a single lab day, since most assays are performed in microtiter plates for which automation solutions exist. Technological advances have further led to the availability of assays with very high sensitivity (fg/ml) (67) . Nevertheless, the number of protein assays and degree of multiplexing remains limited in most applications, in particular when compared to MS. Challenges for immunoassays relate to interference, incompatibility of assay components causing cross-reactivity, different sample dilutions needed for reaching the optimal analytical window, assay specificity, and analytical selectivity (68).
In the long run, technologies that are capable of measuring proteins in multiplex and in a large number of samples will be beneficial for rapid analysis of plasma (69) . One attractive solution is described for coupling multiplexed protein detection with read-out by DNA and to profile more than 90 proteins in a single assay (70, 71) ; they have been used and applied in extensive sample sets (72, 73) . While these proximity extension assays use two binders per target protein, other large scale techniques employ single affinity reagents for high multiplexing capabilities. Those exist on planar arrays (74) as well as on color-coded beads (75), but both come at the expense of sensitivity and specificity, hence require complex validation schemes to assure the identity of the captured protein (76) . Another single binder concept that has seen broad usage is based on modified aptamers that have been engineered to both enrich proteins from plasma and serve as the detection agent (77) . The signatures of the obtained plasma profiles were associated with the protein quantitative trait loci (pQTLs) for validation (78) . Recently, the system has been expanded in the number of targets per assay to 3000 proteins (79) , and assays with 5000 proteins are under development although have not been released as of September 2017 (personal communication). The utilized selection technology and introduction of additional modifications may be one approach to enable the generation of even larger libraries of affinity binders, possibly reaching a possible proteome-wide coverage (80) .
To provide insights into the current portfolio of immunoassays with data from MS, we collected protein assays offered by five commercial immunoassays providers, as introduced above (see Comparisons with RNA abundances). Cumulatively, these five resources constituted 1918 unique targets as of spring 2017, and provide an alternative starting point for a description of the protein assays with plasma. Out of these 1918 proteins, a set of 831 proteins were only detectable by immunoassays when compared to the 2017 build of the Human Plasma PeptideAtlas, leaving 1087 proteins detected in both. The 2017 Human Plasma PeptideAtlas contained a further 2422 proteins that remained addressed only by MSbased methods. We investigated the functional differences between the proteins covered by the two technologies by assessing their Gene Ontology (GO) term distribution using ToppCluster (81) . This revealed that terms for cytokine related proteins were enriched for immunoassays (GO:0005126, GO:0005125, GO:0008009, GO:0042379). For MS, terms related to structural elements (GO:0005198, GO:0008092, GO:0003779, GO:0051015) were enriched (see also Supplementary Table 2 ). This indicates that (i) many low abundant proteins are still difficult to detect in plasma when using MS and that (ii) cellular proteins are found in plasma but are underrepresented in the portfolio of immunoassays. Lastly, our investigation revealed 1087 proteins found to be detectable with both technologies. GO analysis for these proteins revealed terms such as protein complex binding (GO:0032403; N =172), extracellular space (GO:0005615; N =466), cell mobility (GO:0048870; N =304), localization (GO:0051674; N =304) and cell migration (GO:0016477; N =295). These ~1000 proteins can provide a starting point for comparing the two technologies with the purpose of validating each other in increasing numbers of samples, studies and diseases. Eventually, databases such as PeptideAtlas should also be created for the widely used immunoassays to collect data and the concentrations of proteins found in plasma. These initiatives could also follow examples of the NCI assay portal (82) that currently hosts 1,517 quantitative mass spectrometry-based proteomic assays targeted for 820 proteins. In this portal, 374 assays listed for plasma or serum derived samples target 192 unique proteins.
MS. The immunoassays are attractive for studies with larger sample numbers, especially if the amount of material is limited, but still less for de novo discovery purposes.
Quantification remains a challenge for today's immunoassay, since different standards are often used by different assay providers, and their detectability may differ from that of the protein found in-vivo. The emerging systems that offer either highly multiplexed or highly sensitive assays will accelerate our knowledge about the plasma proteome and move beyond the well-studied markers of inflammation. Specificity also remains a major challenge for affinity assays, as reflected in the goals of the International Working Group on Antibody Validation (61) .
Considerations about samples in plasma proteomics
Studies aiming to determine the plasma proteome have largely been limited either by the number of targets or in terms of sample numbers. It is therefore likely that, if only a few phenotypes are used, the initial indications cannot be confirmed in an independent set of samples. Hence, the sample number of plasma proteomic studies must increase. Furthermore, plasma is a specimen that is attractive because it is accessible from a large number of subjects and frequently hosted by biobanks, although many are populated mainly with blood sera (83) . Since the recommendations of the Human Proteome Project in 2006 (3), most plasma samples have used EDTA as anticoagulant; however, some specimens are still anticoagulated with heparin or citrate. Further, multitudes of dried blood spot cards known as Guthrie cards are available since the early 1960's for all newborns almost worldwide providing a large resource for blood-based proteomics (84) (85) (86) . This provides opportunities for new discoveries and is assisted by expanded metadata about each donor (health status and history) as well as the pre-analytical conditions related to the sample. However, both must be acknowledged and considered more carefully. The community is indeed becoming more aware that these sample related parameters may contribute to the detectability of a protein and thereby influence the outcome and reproducibility of a study (87) (88) (89) . Hence, guidelines for the parameters related to the sample, such as blood draw (time point of collection, location), collection procedure (tube type, handling conditions), storage (aliquoting, container, temperature), use (thawing procedure, freeze-thawing cycles) as well as alternative formulation (dried plasma or blood spots), should therefore be considered and included in the experimental planning and downstream data analysis. A categorization of sample-related parameters can already be obtained (90) and a wider use of such codes will further enhance the validity of studies in plasma.
Conclusion
The advances in MS technologies continue to push our ability to detect and quantify a large number of proteins with high specificity and quantitative accuracy. Yet, affinity capture reagent technologies outperform MS in terms of sensitivity and speed. Ongoing efforts to better characterize affinity capture reagents in a given sample holds the potential to improve the specificity and reliability of the assays in which these are used. The combination of these two technologies is probably underutilized today, having the potential to combine the sensitivity of affinity capture and specificity of MS, albeit still with the lower speed of MS. We have presented the 2017-04 latest build of the Human Plasma PeptideAtlas, with 3509 core neXtProt proteins meeting guideline # 15 of the HPP MS Data Interpretation Guidelines. In comparison with older plasma builds, the addition of datasets with high resolution MS2 spectra have dramatically increased the number of distinct peptides observed and the sequence coverage, although the increase in the number of proteins was less pronounced. More datasets will be added as they are deposited into the public ProteomeXchange repositories. Datasets that use new instrumentation, additional proteases beyond trypsin, and additional enrichment strategies are most likely to continue increasing the total number of proteins successfully detected in human plasma samples via MS.
Challenges remain-when is the project considered closed? Human variability is enormous and so individual differences in the plasma proteome will be apparent and cloud the analyses and interpretation. For example, tissue leakage markers from growing juveniles need to be distinguished from similar or identical markers present in adults undergoing tissue healing and repair after pathology or injury. Moreover, nutritional status, diurnal variation and hormonal status will all need to be considered and hallmark proteins subclassified accordingly. Nonetheless, annotating the Human Plasma Proteome Project heralds an important achievement necessary to define and form baselines for disease biomarker discovery and monitoring before and during treatment.
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